Type 2 diabetes (T2D) is generally regarded as a metabolic disorder disease with various phenotypic expressions. Traditional Chinese medicine (TCM) has been widely used for preventing and treating diabetes. In our study, we demonstrated that Cyclocarya paliurus formula extractum (CPE), a compound of TCM, can ameliorate diabetes in diabetic rats. Transcriptome profiles were performed to elucidate the antidiabetic mechanisms of CPE on pancreas and liver. Pancreatic transcriptome analysis showed CPE treatment significantly inhibited gene expressions related to inflammation and apoptosis pathways, among which the transcription factors (TFs) nuclear factor kB (NF-kB), STAT, and miR-9a/148/ 200 may serve as core regulators contributing to ameliorate diabetes. Biochemical studies also demonstrated CPE treatment decreased pro-inflammatory cytokines (tumor necrosis factor alpha [TNF-a], interleukin [IL]-1b, and IL-6) and reduced b cell apoptosis. In liver tissue, our transcriptome and biochemical experiments showed that CPE treatment reduced lipid accumulation and liver injury, and it promoted glycogen synthesis, which may be regulated by TFs Srebf1, Mlxipl,. Taken together, our findings revealed CPE could be used as a potential therapeutic agent to prevent and treat diabetes. It is the first time to combine transcriptome and regulatory network analyses to study the mechanism of CPE in preventing diabetes, giving a demonstration of exploring the mechanism of TCM on complex diseases.
INTRODUCTION
Type 2 diabetes (T2D) is a complex and heterogeneous disease caused by insulin resistance and pancreatic b cell failure. 1 Although insulin resistance exists in all stages from pre-diabetes to overt diabetes, the onset of diabetes and its progression is largely determined by the progressive failure and apoptosis of the pancreatic b cells. 2 Growing evidence suggests that islet inflammation plays an important role in b cell failure and apoptosis. 3 Currently, although the available therapies for diabetes are some western medications or insulin, management of diabetes with fewer side effects at lower costs is still a big chal-lenge. 4, 5 Herbal medications can be a good alternative to replace or at least supplement western medications. 6 Traditional Chinese herbal medicines have been used for a long time to treat diabetes. 7 Accumulated evidence demonstrates that many of these have beneficial effects on the prevention and treatment of diabetes and its complications. 8 In particular, traditional Chinese medicine (TCM) with compound recipes has been widely applied as a clinical medication in diabetes. 9, 10 Cyclocarya paliurus formula extractum (CPE), a compound of TCM, consists of 4 crude plant products: Cyclocarya paliurus, Dendrobium, Morus alba L., and Pericarpium Citri Reticulatae. It was reported that the extract of Cyclocarya paliurus significantly decreased fasting blood glucose (FBG) level, protected pancreas islet from injury, and increased the level of serum insulin in diabetic mice. 11 The other 3 crude plant products are also effective in improving diabetes. Several studies indicated that Dendrobium decreased blood glucose by stimulating the secretion of insulin in diabetic rats. 12 Morus alba L. and Pericarpium Citri Reticulatae exhibit anti-diabetic effects through protecting pancreatic b cells and increasing the content of liver glycogen. 13, 14 Therefore, the compound of Cyclocarya paliurus, Dendrobium, Morus alba, and Pericarpium Citri Reticulatae may have more beneficial antidiabetic effects.
Undoubtedly, the recent development of next-generation sequencing technology, particularly RNA sequencing (RNA-seq) and microRNA sequencing (miRNA-seq), has provided a more comprehensive view of the transcriptional landscape for complex diseases at different layers, 15 which offers insights into molecular mechanisms of disease and bridges the gap between genotype and phenotype. Both of the two technologies have been widely used in diabetic research, and they have identified some key factors relevant to diabetes, such as Bcl-2 16 and miR-375. 17 Moreover, transcription factors (TFs) and miRNAs are two key types of gene expression regulators, and their co-regulation has been studied in biological processes and diseases. 18 However, their co-regulation of an anti-diabetic mechanism rarely has been studied, especially for TCM.
In this study, we validated that CPE treatment ameliorated diabetes in diabetic rats induced by a combination of high-fat diet (HFD) and dexamethasone (DEX), and transcriptomic profiles based on RNAseq and miRNA-seq were performed on the pancreas and liver to explore the molecular mechanisms. Our results demonstrated that CPE could be a potential anti-diabetic agent to prevent and treat diabetes and its complications.
RESULTS

CPE Alleviates Hyperglycemia and Improves Glucose Tolerance in Diabetic Rats
To investigate the anti-diabetic effect of CPE, HFD combined with DEX was used to induce diabetic rats. The dosage of 600 mg/kg body weight was chosen in our subsequent study since the dosage was better in our preliminary experiments ( Figure S1A ). As indicated, CPE treatment significantly decreased FBG compared to the model group ( Figure 1A) . At the end of 5 weeks' treatment, the body weights of the CPE-treated group were much higher than the model group. In contrast, the food intake showed the opposite tendency (Figures S1B and S1C). Results of the oral glucose tolerance test (OGTT) and area under the curve (AUC) showed that glucose intolerance began to occur at the end of 3 weeks in the model group and CPE treatment improved glucose tolerance ( Figures 1B and 1C ). Especially, CPE treatment decreased blood glucose level at 30, 60, and 120 min after glucose loading compared with that of the model group at the end of 5 weeks' treatment ( Figure 1D ). The AUC was also significantly decreased after CPE treatment ( Figure 1E ).
To explore how CPE treatment helped to resist hyperglycemia, we detected levels of insulin. There were significant increases in insulin levels both in the serum and pancreas in the CPE-treated group compared with the model group ( Figures 1F and 1G ). These results suggested that CPE treatment alleviated diabetes in diabetic rats by increasing insulin secretion.
Transcriptome Analysis Demonstrates that CPE Protects the Pancreas by Inhibiting Inflammation and Apoptosis Pathways
To understand the molecular mechanisms of CPE alleviating diabetes, we investigated the transcriptome profiling of the pancreas and liver in three groups, respectively. In pancreas, 16,109 genes (fragments per kilobase of transcript per million fragments mapped [FPKM] > 1) and 278 miRNAs (TPM [tags per million reads] > 10) were detected ( Figures S2A and S2B ). We identified 1,644 differentially expressed genes (DEGs) in the comparison of versus model control groups, and 986 DEGs were detected in the CPE-treated versus model groups. Interestingly, 646 common genes emerged in both comparisons (Figure 2A ). The majority of the 646 genes were downregulated in the CPE-treated group and upregulated in the model group, and these were mainly related to inflammatory or immune response (cytokine-signaling pathways, NOD-like/Toll-like/nuclear factor kB [NF-kB] pathways) and apoptosis processes ( Figure 2B ). The results suggested that CPE treatment exhibited anti-diabetic effects probably through inhibiting inflammation and its induced apoptosis. Pathway crosstalk analysis for these genes showed that CPE treatment suppressed the expression of inflammatory factors and their receptors, such as interleukin and interferon family members (interleukin [IL]-1b/IL-1br/IL-17/IL-17R and interferon [IFN]-g/IFN-gR). Then it inhibited inflammation-related pathways and the downstream biological processes like Jak-STAT/NF-kB, and it alleviated apoptosis of islet cells to ameliorate diabetes ( Figure 2C ).
Results of miRNA-seq analysis showed that miR-148/143 and let-7 family members, including let-7a/c/i, accounted for 70% ( Figure S2C ). Particularly, 27 differentially expressed miRNAs (DEMs, 23 upregulated and 4 downregulated) between the two comparisons were selected for further analysis ( Figure 3A ). Most of the DEMs have been confirmed to be involved in the development of diabetes. Upregulation of miR-146/ 21/222 promotes inflammation-mediated b cell damage and apoptosis, 19, 20 which were downregulated under CPE treatment ( Figure 3A ).
To investigate the roles of miRNAs and TFs participating in the anti-diabetes under CPE treatment, we constructed a miRNA-TF-gene regulatory network using DEMs and DEGs related to inflammation and apoptosis (Figure S3 ). The network demonstrated that TFs (e.g., STAT and NF-kB) and miRNAs (e.g., miR-200/9a/148a) were the hub nodes (Figure 3B ). CPE treatment upregulated miR-148a/9a, which inhibited TFs NF-kB and STAT and downregulated inflammatory and apoptotic genes ( Figure 3B ). These data were consistent with previous reports that miR-148a-3p and miR-9a inhibited inflammation through inhibiting NF-kB activation and targeting the Jak/ STAT-signaling pathway. 21, 22 miR-200c can inhibit the NF-kB-signaling pathway and downregulate gene expressions of inflammatory cytokines, 23 which were upregulated under CPE treatment. The regulatory network and functional enrichment analysis of DEGs indicated that CPE may improve diabetes by inhibiting b cell apoptosis induced by inflammation.
CPE Treatment Protects the Pancreas against Inflammation and Oxidative Stress Damage
To validate the CPE effects on alleviating inflammation and apoptosis by bioinformatics analysis, inflammatory cytokines IL-1b, IL-6, and tumor necrosis factor alpha (TNF-a) were examined using ELISA kits. Results indicated that CPE treatment reduced the levels of IL-1b and TNF-a both in the serum and pancreas, as well as IL-6 in the serum ( Figure 4A ). Pancreatic histopathological section showed that pancreas islet of the model group was seriously damaged, characterized with an irregular shape and disorder islet cells, compared to that in the control group ( Figure 4B ). Improved signs of destruction could be seen in the islets following CPE treatment. An average of 84.2% apoptotic cells was found in the model group, which was decreased to an average of 6.8% after CPE treatment (Figure 4C ). As indicated, the expressions of genes related to inflammation and apoptosis, including NF-kB/TNF-a/IL-1b/IFN-g/STAT1/ IL-17R/Caspase-3/Bax/Bcl2, were significantly downregulated after CPE treatment ( Figure 4D ). At the same time, CPE treatment upregulated gene expressions of Ins1 and Ins2 significantly, which were inhibited in the model group ( Figure 4E ). These findings were consistent with our RNA-seq and biochemical results that CPE treatment inhibited inflammation and apoptosis and increased insulin levels in the serum and pancreas ( Figures 2B, 1F , and 1G). Therefore, our results demonstrated that CPE treatment reduced pancreas islet injury and inhibited b cell apoptosis through reducing inflammation, which guaranteed the normal secretion of insulin to reduce blood glucose.
Chronic hyperglycemia is responsible for the oxidative stress observed in the pancreatic b cells. 24 b cells are susceptible to oxidative damage because the islet has the lowest intrinsic antioxidant capacity. 25 The level of malondialdehyde (MDA), concentration of glutathione, and activity of antioxidant enzymes superoxide dismutase (SOD) were detected ( Figure S4 ). A great increase of serum MDA level and decreases of glutathione concentration and SOD activity in the serum and pancreatic tissue were observed in the model group, whereas CPE treatment decreased the level of MDA and increased glutathione concentration and SOD activity significantly. The results indicated that CPE treatment reduced oxidative stress damage.
Transcriptome Analysis and Biochemical Results Indicate that CPE Treatment Regulates Hepatic Lipid and Glucose Homeostasis
The liver controlling glucose and lipid metabolism homeostasis plays key roles in the development of diabetes. 26 Transcriptome-profiling analysis of the liver demonstrated 10,787 genes (FPKM > 1) and 179 miRNAs (TPM > 10) were expressed among the control, model, and CPE-treated groups ( Figures S5A and S5B ). DEGs between CPE treatment and model groups were mainly assigned to lipid accumulation, including nonalcoholic fatty liver disease (NAFLD) and peroxisome proliferator activated receptor (PPAR) pathways, glycolysis, gluconeogenesis, and organ regeneration-related terms ( Figure 5A ). CPE treatment decreased the expression levels of genes involved in NAFLD and gluconeogenesis, which were increased in the model group ( Figures 5B and 5C ). Meanwhile, fatty acid metabolism and organ regeneration processes were strengthened in the CPE-treated group ( Figure 5A ). In particular, fatty acid b oxidation and lipid transport-associated genes, such as Ehhadh, Fabp7, and Apoa2, were upregulated under CPE treatment; while lipid synthesis-associated genes, including Fasn, Fads6, Acsm3, Cidea, and Acox2, were downregulated ( Figure 5B ). Therefore, CPE treatment decreased lipid synthesis and increased lipid oxidation and transport, as well as inhibited gluconeogenesis. miRNA profiling showed that the expressions of miR-122, miR-143, and miR-21 accounted for nearly 70% of all miRNAs ( Figure S5C ). Some miRNAs were significantly changed after CPE treatment, such as miR-122/143/192 being significantly upregulated in the CPE-treated group compared with the model group ( Figure 6A) . To understand the miRNA function in liver, we constructed a miRNA-TF-target regulatory network for DEMs and DEGs enriched in the above functions ( Figure 5A ; Figure S6 ). miR-122/128/192 and their target genes were hub nodes in the work ( Figure 6B ). TFs Srebf1/ Mlxipl were the major regulators of de novo lipid synthesis, 27, 28 and these were the main hub TFs in this network. miR-122 targeting Srebf1 controlling the lipid accumulation participated in the development of NAFLD. 29 miR-122/192 regulated the expression of Srebf1 and its downstream target genes, such as Fasn and Cidea, which were involved in the lipid synthesis. 30, 31 CPE treatment upregulated the expression of miR-128, which inhibited the expression of Mlxipl ( Figure 6B ). Mlxipl targeted the Thrsp gene, which regulated fat synthesis by directly activating some classical lipogenic enzymes, such as Fasn. 32, 33 Thus, CPE treatment may reduce lipid synthesis by the miR-122/192-Srebf1-Fasn/Cidea and miR-128-Mlxipl-/Thrsp-Fasn pathways. NAFLD increases the susceptibility of the liver to acute liver injury and hepatocyte apoptosis. 34 However, CPE treatment enhanced liver development and the organ regeneration process ( Figure 5A ). Our results suggested CPE treatment reduced lipid accumulation and liver injury by enhancing fatty acid oxidation and transport, as well as decreasing triglyceride synthesis. The results of morphological observation and biochemical experiment were consistent with transcriptome profiling. CPE treatment decreased the level of serum free fatty acids (FFAs) and the contents of triglycerides (TGs) and total cholesterol (TC) in the liver, and it increased the content of liver glycogen compared to that in the model group ( Figures 7A and 7C) . The histopathological section also demonstrated that CPE treatment reduced fat accumulation (Figure 7B) . CPE treatment significantly decreased the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), markers of hepatic function, which were elevated in the model group ( Figure 7D ). Therefore, CPE treatment reduced fat accumulation, promoted glycogen biosynthesis, and alleviated liver injury.
DISCUSSION
In T2D, pancreatic b cells fail to produce enough insulin to meet the body's demand, partly due to an acquired decrease in b cell mass. 35 Notably, increased b cell apoptosis is an important factor contributing to b cell loss, 36 and protecting pancreatic b cells from apoptosis is beneficial to ameliorate T2D. Meanwhile, the onset and progression of T2D is often associated with dyslipidemia, which indicates a progressive impairment in hepatic control of glucose and lipid fluxes in the liver. 37, 38 In the present study, our results demonstrated that CPE treatment attenuated inflammation and pancreas injury and inhibited b cell apoptosis, which ensured the normal secretion of insulin. Supplementation with CPE reduced lipid accumulation, increased FFA oxidation and transport, and eventually decreased liver injury.
Insulin is the only hormone that decreases blood glucose in the body, which is secreted by pancreatic islet b cells. b cell dysfunction and apoptosis result in a decrease in insulin and lead to hyperglycemia. 39 It was reported that islet inflammation played an important role in b cell apoptosis. 3 In our study, CPE exhibited anti-inflammatory effects, which reduced b cell apoptosis and then guaranteed the secretion of insulin, contributing to the improving diabetes ( Figure 8A ). NF-kB and Jak-STAT pathways play vital roles in the b cell apoptosis induced by inflammation cytokines. 3 Pro-inflammatory cytokines, such as IL-1b, TNF-a, and IL-17, induce the activation of NF-kB. 40 IFN-g can activate the Jak-STAT pathway. 41 CPE treatment inhibited gene expressions of TNF-a/IL-1b/NF-kB/IFN-g/STAT1/IL-17R and then reduced b cell apoptosis ( Figure 4D ). On the other hand, CPE treatment enhanced the gene expression of insulin, which increased the levels of insulin ( Figures  1F, 1G, and 4E) . miRNAs have made an important contribution to regulate gene expression observed in dysfunctional b cells. 42 CPE treatment downregulated miR-146/21/222, related to inflammation and apoptosis. 19 CPE treatment downregulated let-7, which was reported to reduce glucose-induced insulin secretion. 43 The feedback loops, miR-200/148a/NF-kB and miR-9a/STAT, as core nodes regulating inflammation-related signaling pathways, contributed to the improving diabetes after CPE treatment ( Figure 3B ). Given the above results, CPE treatment protected b cells from apoptosis induced by inflammation.
The combination of HFD and DEX induced serious lipid accumulation, which resulted in NAFLD and liver injury. 44 NAFLD was caused by the imbalance between lipid synthesis and lipid oxidation and transport, which is associated with an increased risk of developing diabetes. 26 In our study, CPE treatment significantly reduced lipid synthesis and enhanced lipid oxidation and transport, as well as promoted glycogen synthesis, and eventually it decreased liver injury and blood glucose ( Figure 8B ). CPE treatment upregulated the PPARa signal pathway, which activated Cd36, Fabp7, and Ehhadh, contributing to the decrease of cholesterol and the enhancements of b oxidation and transport of fatty acid (Figures 5A and 5B) . The upregulation of the PPARa signal pathway also inhibited gluconeogenesis. 45 Meanwhile, CPE treatment upregulated miR-143, which inhibited the lipogenesis by suppressing the expression of Fasn. 46 Moreover, the regulatory network between miR-122/192/128 and Srebf1/ Mlxipl played an important role in improving diabetes, which reduced lipid synthesis and glycolysis in the liver ( Figure 6B ). On the other hand, CPE treatment enhanced glucose utilization by downregulating gluconeogenesis and promoting glycogen synthesis (Figures 5A, 5C, and 7C) . Therefore, CPE treatment ameliorated impaired glucose and lipid homeostasis by reducing lipid accumulation and increasing lipid transport, as well as increasing glucose utilization.
In summary, we validated that CPE treatment could ameliorate diabetes by protecting pancreas islet from injury and inhibiting b cell apoptosis in diabetic rats. It was the protective effects of CPE on b cells that guaranteed the normal secretion of insulin, which decreased the blood glucose. In addition, CPE treatment improved impaired glucose and lipid metabolism by reducing lipid accumulation and promoting glycogen biosynthesis in liver tissue, which contributed to ameliorating diabetes. Therefore, CPE could be an alternative for preventing and treating diabetes. Furthermore, our study indicated that transcriptome profiles based on RNA-seq and miRNA-seq could provide insights for exploring the potential mechanism of TCM on complex diseases.
MATERIALS AND METHODS
Preparation of the CPE CPE contained 4 crude plant products, consisting of Cyclocarya paliurus, Dendrobium, Morus alba L., and Pericarpium Citri Reticulatae. Briefly, leaves of Cyclocarya paliurus and stems of Dendrobium, Morus alba, and Pericarpium Citri Reticulatae were mixed in the ratio of 4:2:2:1 (dry weight). The mixture was decocted with 20 vol (v/w) boiling distilled water for 2 hr, after which the filtrate was collected and the residue was decocted once again. The process was repeated three times. Extractions of filtrates were collected and then concentrated in vacuo to obtain CPE. The yield was 28.6% relative to the original crude plant products. It was dissolved in physiological saline before use. The phenol-sulfuric acid colorimetric titration method was used for the determination of polysaccharide content, which was 5.12/100 g CPE. The estimation of total flavonoid content was performed by the aluminum chloride method; it was 2.24/100 g CPE.
Animals
Male Sprague-Dawley rats (200 ± 20 g) were purchased from Hubei Province Center for Disease Control and Prevention. Rats were separated into control, model, and CPE-treated groups, respectively. Rats in the control group were fed with a standard diet for 5 weeks. The model and CPE-treated groups were fed with a standard diet for the first week, and then with a HFD (sucrose 15%, lard oil 10%, egg yolk powder 5%, cholesterol 1%, bile acid sodium 0.2%, and standard diet 68.8%) for the second and third weeks. At the fourth and fifth weeks, the model and CPE-treated groups were injected intraperitoneally with DEX (0.8 mg/kg) daily based on the HFD feeding. CPE-treated groups received an oral daily dose of CPE 600 mg/kg body weight, whereas the control and model groups received only the equivalent amount of physiological saline.
At the end of the experiment, all rats were fasted overnight and anesthetized with pentobarbital sodium. Blood samples were obtained from abdominal aorta, and sera were collected and stored at À20 C in a freezer until use. The pancreas and liver tissues were isolated, washed with physiological saline solution, immediately frozen in liquid nitrogen, and stored at À80 C. The animal experimental protocol was approved by the Animal Experimentation Ethics Committee of Huazhong University of Science and Technology, and it was performed in accordance with guidelines approved by the Science and Technology Department of Hubei Province. Measurement of Blood Glucose, Insulin, and Oral Glucose Tolerance FBG was measured in blood collected from the tail. A blood glucose meter (Accu-Check Active 1, Roche, Basel, Switzerland) was used for blood glucose detection. An OGTT was performed at the end of 3 and 5 weeks. After an overnight fast, blood glucose levels were measured immediately before and 30, 60, and 120 min after glucose administration at 2.5 g/kg (Sigma, USA). Insulin levels both in the serum and pancreas were measured with insulin ELISA Kit (Nanjing Jiancheng Bioengineering Institute, China).
Analysis of Inflammatory Cytokines and Oxidative Stress in Serum and Pancreatic Tissue
Levels of TNF-a, IL-1b, and IL-6 were measured with commercial ELISA Kits (Cloud Clone, China). The level of MDA and activities of SOD and glutathione were measured using commercial kits purchased from Nanjing Jiancheng Bioengineering Institute (China). The protein concentration of the pancreas was assayed with a BCA Protein Assay Kit (Beyotime Biotechnology, China).
Measurement of FFA, AST, and ALT in Serum and TG, TC, and Glycogen in the Liver Liver glycogen was assayed using a liver glycogen assay kit. The level of serum FFA and contents of TG and TC in the liver were detected using corresponding kits. All assay kits used were obtained from Nanjing Jiancheng Bioengineering Institute. The activities of serum AST and ALT were detected with an automatic biochemical analyzer in Wuhan general hospital of Guangzhou military (China). The protein concentration of the liver was assayed with a BCA Protein Assay Kit (Beyotime Biotechnology, China).
Histopathological Examination
Histopathological examinations of pancreas and liver tissues were performed as in the literature. 11 Briefly, pancreatic and liver tissues were dehydrated in alcohol, embedded in paraffin, and sectioned at 5-mm thickness using a microtome (RM2235 ccwUS, Leica Microscopy System). The sections were dewaxed in xylene and then in a graded series of ethanol to elute xylene, washed with water, and stained with H&E. Histopathological examinations were carried out under a light microscope (DM3000, Leica Microscopy System, Germany).
TUNEL Staining
Apoptotic pancreatic b cells were visualized by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining according to the manufacturer's instructions (Bioyear Biological Technology). Briefly, the sections were digested with proteinase K and washed three times. After that, the sections were incubated with terminal deoxynucleotidyl transferase (TdT) buffer at 37 C for 60 min and then incubated with dUTP. At last, streptavidin-labeled horseradish peroxidase (HRP) and diaminobenzidine (DAB) were added for chromogenic reaction.
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